Cass Review Team
TransLucent.Org.UK advocates for the transgender and gender-diverse community in the UK and was awarded the accolade of “LGBT Organisation of the Year” (National Diversity Awards 2022) before we rebranded and became a Community Interest Company (CIC) in November 2022.
We have been described by the Equality and Human Rights Commission as a “key stakeholder” for the trans community and have made three human rights submissions to the United Nations. In November 2023, we held our first London Conference just 100 metres from Parliament.
Our mission is simple.
We campaign for visibility, acceptance, legal recognition and healthcare for our community – countering the misinformation and lies told by transphobic/trans-hostile sources.

Rob Cleary PhD
he/him (cisgender)
With a background in psychology, and following a thirty year career in and around the NHS (most recently a lengthy period as Content Director for the NHS website), Rob has joined TransLucent to contribute research and analysis.

S
cisgender
CLASSIFIED

M
trans woman
CLASSIFIED

CF
she/her
trans woman

C
trans woman
CLASSIFIED

D
cisgender
CLASSIFIED

N
she/her
trans woman
The Cass Review briefing note examines the Cass Review’s recommendations for gender identity services. TransLucent’s report identifies concerns from service users, professionals, and human rights organisations, and offers solutions. Continue Reading The Cass Review – Briefing Note
Gender-Critical Feminism – The Wrecking of Lives. Opinion – posted by Sophie 23/12/24 Talk to…
Our Year End Operational Review highlights TransLucent’s advocacy for the trans and non-binary community, including meetings with government officials to discuss healthcare and policy reform. The review also acknowledges financial challenges, celebrates the distribution of their report “TRANS: A Community Under Attack,” and outlines TransLucent’s position on the Cass Report, puberty blockers, and single-sex spaces.
Continue Reading TransLucent Year End Operational Review
TransLucent’s position statement argues against the ban on puberty blockers (GnRH analogues) for young trans people, citing insufficient evidence and potential bias in the Cass Review. Continue Reading TransLucent Puberty Blocker (GnRH Analogues) Position Statement